| bevacizumab based treatment |
| bevacizumab plus trastuzumab plus docetaxel |
| la/mBC - HER2 positive | |
| la/mBC - HER2 positive - (neo)adjuvant (NA) | |
| la/mBC - HER2 positive - 1st Line (L1) 5 | |
| la/mBC - HER2 positive - 2nd Line (L2) 13 | |
Comparator:
vs trastuzumab plus docetaxel;
Risk of bias:
low;
some concerns;
high;
NA;